FULVESTRANT
Duodenal Neuroendocrine Tumor G1
M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Duodenal Neuroendocrine Tumor G1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ribociclib M.D. Anderson Cancer Center | Phase 2 | B |
Letrozole M.D. Anderson Cancer Center | Phase 2 | B |
Zoladex M.D. Anderson Cancer Center | Phase 2 | B |
LEUPROLIDE M.D. Anderson Cancer Center | Phase 2 | B |
Cediranib M.D. Anderson Cancer Center | Phase 2 | B |
Same molecule, other indications
FULVESTRANT is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →